Table 2.
Response of patients with measurable disease
| Response | All | RAS mutant | RAS WT | BRAFV600E mutant | RAS/BRAFV600E WT |
|---|---|---|---|---|---|
| n = 48 | n = 18 | n = 24 | n = 8 | n = 16 | |
| PR | 34(70.8%) | 13 (72.2%) | 19 (79.2%) | 4 (50.0%) | 15 (93.8%) |
| SD | 9 (18.8%) | 4 (22.2%) | 3 (12.5%) | 2 (25.0%) | 1(6.3%) |
| PD | 4(8.3%) | 1 (5.6%) | 2 (8.3%) | 2 (25.0%) | 0 |
| NE | 1 (2.1%) | 0 | 0 | 0 | 0 |
| NED | 1(2.1%) | 0 | 0 | 0 | 0 |
| ORR | 70.8% | 72.2% | 79.2% | 50.0% | 93.8% |
| DCR | 89.6% | 94.4% | 91.7% | 75.0% | 100% |
Genotype and response rate, Fisher exact probability test (two-sided), BRAF V600E mutant vs. RAS/BRAFV600E WT, p = 0.028
DCR Disease control rate, NED No evidence of disease, ORR Objective response rate, PR Partial response, SD Stable disease, WT wild-type